期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

替吉奥胶囊联合紫杉醇治疗术后复发或转移性胃癌的疗效观察 被引量：12

下载PDF
导出
摘要 目的探讨替吉奥胶囊联合紫杉醇全身化疗对术后复发或转移性胃癌的近期疗效及不良反应。方法28例手术后复发或转移的胃癌入组,给予替吉奥胶囊联合紫杉醇方案(替吉奥胶囊按照体表面积给予40～60 mg,2次/d,第1～14天;紫杉醇135 mg/m2,第1天,静滴,3周重复)化疗,患者均接受至少2个周期全身化疗后评价疗效。结果总有效率为49.99%(14/28),其中完全缓解率7.14%、部分缓解率42.85%、稳定率21.43%,临床获益率达到71.42%。主要毒副作用有骨髓抑制、周围神经毒性及胃肠道反应。结论替吉奥胶囊联合紫杉醇治疗术后复发或转移性胃癌疗效可,毒副反应可以耐受。
作者 党琦 杨红艳 刘杰 高卫
机构地区 山东大学附属济南市中心医院
出处 《山东医药》 CAS 2013年第1期93-94,共2页 Shandong Medical Journal
关键词 胃肿瘤 替吉奥 紫杉醇 抗肿瘤联合化疗方案
分类号 R735.2 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1孙燕,石远凯著..临床肿瘤内科手册 五版[M].北京:人民卫生出版社,2007.
  • 2马培奇.抗肿瘤新药替吉奥钾研究进展[J].中国医药导刊,2007,9(6):499-502. 被引量：54
  • 3Kim JY, Do YR, Park KU, et al. Multicenter phase Ⅱ trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer [ J ]. Cancer Chemother Pharmacol, 2011,67(3) :527-532. 被引量：1
  • 4Okita A, Miyade Y, Okano K. Effective management of an ad- vanced gastrie caneer patient by TS-1 combined chemotherapy using nasojejunal lube and successful transfer to home care 'after percuta- neous transesophageal gastro-tubing (PTEG) : a case report [ J ]. Acta Med Okayama, 2010,64( 1 ) :67-70. 被引量：1
  • 5Ueda -, Yamagishi H, lehikawa D, et al. Multicenter phase Ⅱ study of weekly paclitaxel plus S-1 combination chemotherapy in pa- tients with advanced gastric cancer[ J ]. Gastric cancer, 2010,13 (3) :149-154. 被引量：1
  • 6Tamura S, Miki H, Okada K, et al. Pilot study of a combination of S-1 and paclitaxel Ior patients with peritoneal metastasis from gastric cancer[J]. Gastric Cancer, 2010,13(2) :101-108. 被引量：1
  • 7周恒根,倪敬中,刘兰芳,程燕,李亚莉,李华年.替吉奥胶囊联合紫杉醇治疗晚期胃癌28例临床观察[J].中国现代药物应用,2011,5(11):3-4. 被引量：11
  • 8晏淼,刘小青,卞保祥,张为民,郑义同.替吉奥胶囊联合紫杉醇治疗进展期胃癌的临床研究[J].中国全科医学,2012,15(9):990-992. 被引量：8

二级参考文献28

  • 1秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量：268
  • 2Yusuke Koizumi,Hirozumi Obata,Akinori Hara,Takashi Nishimura,Kenichiro Sakamoto,Yoshihide Fujiyama.A case of scirrhous gastric cancer with peritonitis carcinomatosa controlled by TS-1~ + paclitaxel for 36 mo after diagnosis[J].World Journal of Gastroenterology,2007,13(3):470-473. 被引量：1
  • 3Ajanj Ja. Docetaxel for gastric and esophageal carcinomas. Oncology,2002, 16 (6) : 89-96. 被引量：1
  • 4Tanaka F, Fukuse T,Wada H, et al. The history, mechanism and clinical use of oral 5-fluoroumcil derivative chemotherapeutic agents. Curr Pharm Biotechnol, 2000, 1 (2) : 137-164. 被引量：1
  • 5Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity to fluoropy rimidines bymetabolic and target enzyme activities in gastric cancer. Gastric Cancer, 2003, 6 ( Suppl 1) :71- 81. 被引量：1
  • 6Yoshisue K, Hironaga K, Yamaguehi S, et al. Reducti on of 5- fluorouracil gastrointestinal ( GI ) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated repeated simultaneous administration of potassium oxonate (Oxo) in rats. Cancer Chemother Phar macol, 2000, 46 (1) : 51-56. 被引量：1
  • 7Yoshisue K, Masuda H,Matsushima E, et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent ( drug combination of tegafur, 5-chloro 2, 4 dihydr oxypyridine, and potassium oxonate ) to rats. Drug Metab Dispos, 2000, 28 (10) : 1162-1167. 被引量：1
  • 8Koizumi W, Akiya T, Sato A, et al. Phase II study of S -1 as first line treatment for elderly patients over 75 years of age with advanced gastric cancer: the Tokyo Cooperative Oncolagy Group study. Cancer Chemother Pharmacol,2010, 65 (6) : 1093-1099. 被引量：1
  • 9Lee JL, Kang YK, Kang HJ, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first line treatment in elderly patients with metastatic or recurrent urtresectable gastric cancer. Br J Cancer, 2008, 99(4) :584-590. 被引量：1
  • 10Kunisaki C, Takahashi M, Makino H, et al. Phase Ⅱ study of biweekly docetaxel and S -1 combination chemotherapy as first line treatment for advanced gastric cancer. Cancer Chemother Pharmacol, 2010,28 (4) :2473-2478. 被引量：1

共引文献67

同被引文献89

  • 1郭颖英,方伟虹,谢淑萍.替吉奥联合奥沙利铂治疗进展期胃癌疗效观察[J].浙江中医药大学学报,2010,34(5):783-783. 被引量：22
  • 2Ikuko Miyazaki,Takashi Kawai,Youji Harada,Fuminori Moriyasu.A predictive factor for the response to S-1 plus cisplatin in gastric cancer[J].World Journal of Gastroenterology,2010,16(36):4575-4582. 被引量：8
  • 3勒世联.不同化疗方案一线治疗老年晚期胃癌的近期疗效分析[J].中国生化药物杂志,2014,34(1):108-110. 被引量：9
  • 4Zhao ZS,Wang YY,Ye ZY,et al. Prognostic value of tumor- related molecular expression in gastric carcinoma[J]. Pathol Oncol Res, 2009,15 (4) : 589-596. 被引量：1
  • 5West HL,Crowley JJ,Vance RB, et al. Advanced bronchio- loalveolar carcinoma:a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714):a Southwest Oncology Group study [J]. Ann Oncol, 2005,16(7) : 1076-1080. 被引量：1
  • 6Lee KW, Im SA, Yun T, et al. Phase ]I Trial of low-dose paclitaxel and eisplatin in patients with advanced gastric cancer[J]. Jpn J Clin Oneol, 2005,35 (12) : 720-726. 被引量：1
  • 7Kim JY,Do YR,Park KU,et al. Multicenter phase II trial of S-l,paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer[J]. Cancer Chemo ther Pharmacol, 2011,67(3) : 527-532. 被引量：1
  • 8Okita A, Miyade Y, Okano K. Effective management of an advanced gastric cancer patient by TS-1 combined chemo- therapy using nasojejunal tube and successful transfer to home care after percutaneous transesophageal gastro-tubing (PTEG) : a case report[J]. Acta Med Okayama, 2010,64 ( 1 ) : 67 -70. 被引量：1
  • 9Ueda Y, Yamagishi H, Ichikawa D, et al. Multicenter phase study of weekly paclitaxel plus S-1 combination chemo therapy in patients with advanced gastric cancer[J]. Gastric Cancer, 2010,13(3) : 149-154. 被引量：1
  • 10Xu X, Wang L, Xu HQ, et al. Clinical comparison between paclitaxel liposome (Lipusu) and paclitaxel for treatment of patients with metastatic gastric cancer[J]. Asian Pac J Cancer Prev, 2013,14(4) : 2591 2594. 被引量：1

引证文献12

二级引证文献90

山东医药
2013年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部